Merz Therapeutics’ XEOMIN ® (incobotulinumtoxinA) receives new therapeutic indication for the United Kingdom
Merz Therapeutics, a business of the Merz Group and a leader in the field of neurotoxins, received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom (UK) for the use of XEOMIN® for the treatment of focal spasticity of the lower limb affecting the ankle joint. The approval, which previously included upper limb spasticity, has now been extended, enabling Merz Therapeutics to offer holistic support to people in the UK living with spasticity who require comprehensive treatment.
“The label extension in the UK is an important step for Merz Therapeutics and the patients that we serve. With the UK becoming the second market, following Japan, to grant approval for the treatment of lower limb spasticity, affecting the ankle joint, it establishes the UK as the pioneering European country in this area. This approval supports our strong commitment to bringing better outcomes to more patients,” says Stefan König, CEO Merz Therapeutics.
Enabling holistic treatment for people living with spasticity
Lower limb spasticity is a consequence of upper motor neuron damage as may occur following e.g. a stroke. Each year, around 41,800 people in England have a stroke that results in spasticity, approximately 66 % of which suffer from spasticity in the ankle.1 XEOMIN®with the active ingredient incobotulinumtoxinA is injected intramuscularly to improve tone. Appropriately qualified healthcare practitioners can now use XEOMIN® to treat lower and upper limbs individually or concomitantly, adjusting the dosage as needed.
John Lambert, Country Manager of Merz Therapeutics UK & Ireland: “This new therapeutic indication supports an extension of the benefit XEOMIN® can bring in the treatment of spasticity. We are very proud that we can now offer an alternative product to help patients in the UK.”
With the new therapeutic indication, the maximum dose of XEOMIN® for the treatment of the lower limb is 400 units per injection. For the combined treatment of upper and lower limb spasticity, the maximum dose per administration is 500 units for the first injection and rising to 600 units for following injections. Accepting that patients should always be administered the lowest effective dose possible, with an increase in total dose patients can now be treated with XEOMIN® for more patterns of spasticity simultaneously than before this new indication. The dosing interval should be at least 12 weeks. The therapeutic indication is based on trial data from Japan, where XEOMIN® was also approved for treatment of the lower limb region in 2021.
Going forward, Merz Therapeutics can thus offer UKpatients being treated for their spasticity a more holistic solution for their treatment.
1. National Institute for Health and Care Excellence Draft scope for the proposed appraisal of botulinum toxin type A (Botox, Dysport and Xeomin) for treating upper and lower limb spasticity associated with stroke Issue Date: July 2014. Available at: https://www.nice.org.uk/guidance/gid-tag499/documents/spasticity-after-stroke-botulinum-toxin-type-a-draft-scope-for-consultation-prereferral-july-20142. (Accessed: 02 June, 2023).
About XEOMIN®
XEOMIN® is effective by weakening the contraction of voluntary muscles. It relieves the muscle tone by inhibiting the release of a neurotransmitter called acetylcholine from the peripheral nerve endings. XEOMIN® is free from complexing proteins and has a low risk of neutralizing antibody formation. XEOMIN® is approved in more than 75 countries worldwide to treat patients with upper and lower limb spasticity, cervical dystonia, blepharospasm and sialorrhea.
About Merz Therapeutics
Merz Therapeutics GmbH is dedicated to improving the lives of patients around the world. With its relentless research, development, and culture of innovation, Merz Therapeutics strives to serve unmet patient needs and realize better outcomes. Merz Therapeutics seeks to address the unique needs of people who suffer from movement disorders, neurological conditions, liver disease, and other health conditions that severely impact patients’ quality of life.
Merz Therapeutics is headquartered in Frankfurt am Main, Germany and is represented in more than 90 countries, with a North America affiliate based in Raleigh, North Carolina. Merz Therapeutics GmbH is part of the Merz Group, a privately held, family-owned company that has dedicated more than 110 years to developing innovations that serve unmet patient and customer needs.
Please visit www.merztherapeutics.com
About Merz
Merz Group is a global, diversified company with its headquarters in Frankfurt, Germany. Its commitment to innovation, long-term perspective, and focus on profitable growth depict the privately owned company that has been around for more than 110 years. Merz Group has the businesses Merz Aesthetics, Merz Therapeutics, Merz Consumer Care, Merz Real Estate and Financial Investments. The company employs 3,969 people in 28 countries worldwide.
To learn more, please visit www.merz.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230607005580/en/
Contact information
Merz Therapeutics GmbH
Agnes Tesch
Global Communications
+49 69 1503 2129
agnes.tesch@merz.de
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IonQ och QuantumBasel förlänger sitt långsiktiga samarbete till nästa generations kvantsystem20.12.2025 21:32:00 CET | Pressmeddelande
IonQ (NYSE: IONQ), världens ledande kvantdatorföretag, tillkännagav i dag ett utökat samarbetsavtal med QuantumBasel, kvantinitiativet vid uptownBasel, Schweiz internationella innovationscampus. Genom det utökade avtalet beviljas QuantumBasel äganderätten till det befintliga IonQ Forte Enterprise-systemet och blir ägare av ett nästa generationens Tempo-system. Det nya avtalet ökar det totala värdet av samarbetet mellan QuantumBasel och IonQ till över 60 miljoner USD samtidigt som IonQ:s roll i Schweiz därigenom förlängs i ytterligare fyra år, t.o.m. 2029. QuantumBasel är IonQ:s officiella innovationscenter i Europa och fungerar som ett nav för europeiska industrier, universitet och forskningsinstitut som vill utforska praktiska kvantdatortillämpningar och få tillgång till IonQ:s senaste storföretagssystem. ”Vårt förlängda samarbete med QuantumBasel utgör en hörnsten i IonQ:s globala strategi”, säger Niccolo de Masi, styrelseordförande och CEO på IonQ. ”QuantumBasel fortsätter att vara
EIG Acquires a 49.87% Stake in Transportadora de Gas del Perú (TgP)19.12.2025 18:42:00 CET | Press Release
EIG, through its managed investment vehicles, acquired a 49.87% equity stake in Transportadora de Gas del Perú S.A. (“TgP”) from Canada Pension Plan Investment Board today. TgP operates Peru’s principal natural gas and natural gas liquids pipelines under a long-term concession, supplying approximately 40% of the country’s power generation. “We are delighted to complete this transaction and embark on the next chapter of our partnership with TgP,” said Matt Hartman, EIG’s Global Head of Infrastructure. “Our priority is to support TgP’s operational excellence and long-term stability, delivering value for customers and stakeholders throughout Peru.” About EIG EIG is a leading institutional investor in the global energy and infrastructure sectors with $24.3 billion assets under management as of September 30, 2025. EIG specializes in private investments in energy and energy-related infrastructure on a global basis. During its 43-year history, EIG has committed over $51.7 billion to the energ
Klarna Partners With Coinbase to Add Stablecoin to Funding Mix19.12.2025 18:00:00 CET | Press Release
Klarna, the global digital bank and flexible payments provider, has partnered with Coinbase to add stablecoin funding to its broad range of traditional sources of funding, which include consumer deposits, long-term loans and short-dated commercial paper. The digital bank plans to raise short-term funding from institutional investors denominated in USDC utilizing Coinbase’s digitally native infrastructure. Adding a USDC-denominated funding source enables Klarna to access USD-like funding directly, tapping into a new pool of institutional investors. “This is an exciting first step into a new way to raise funding,” said Niclas Neglén, Chief Financial Officer, Klarna, “Stablecoin connects us to an entirely new class of institutional investors, and gives us the potential to diversify our funding sources in ways that simply weren't possible a few years ago. This is just the beginning of how digital assets can work alongside our traditional funding sources." Klarna chose Coinbase for this ini
CyberArk Named a Leader in IDC MarketScape: Worldwide Integrated Solutions for Identity Security 202519.12.2025 17:00:00 CET | Press Release
CyberArk (NASDAQ: CYBR), the global leader in identity security, today announced that it has been recognized as a Leader in the IDC MarketScape: Worldwide Integrated Solutions for Identity Security 2025 Vendor Assessment. CyberArk extends dynamic privilege controls across all identity types with its unified platform, enabling organizations to improve efficiencies and streamline security operations. This IDC MarketScape report notes, “More change has occurred in the identity security marketplace in the past two years than in almost a decade. Vendors are entering a new phase defined by the emergence of intelligence technologies, none of which are specifically defined by any industry standards. Though different by design, the new adjacent IAM offerings are largely focused on improved vulnerability and threat management visibility and automated and predictive attack detection capabilities.” It also notes, “By addressing these evolving identity types within a unified framework, CyberArk enh
New York Liberty and Ant International’s Alipay+ Announce Multiyear Partnership Focused on Empowerment, Sustainability and Youth Development19.12.2025 14:30:00 CET | Press Release
The New York Liberty and Ant International’s Alipay+, a leading cross-border fintech services platform based in Singapore, today announced a multiyear partnership, making Alipay+ an Official Sponsor and Innovation Partner for Sustainability of the New York Liberty. Through this partnership, Alipay+ and the Liberty will jointly support community programs designed to advance community empowerment, environmental sustainability and youth development across New York City. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219678825/en/ Peng Yang, CEO, Ant International and Clara Wu Tsai, Vice Chair, Brooklyn Sports and Entertainment; Governor, New York Liberty “Our partnership with Alipay+ goes beyond the game,” said Keia Clarke, Chief Executive Officer, New York Liberty. “Together, we are investing in the future of New York—its people, its environment, and its youth. Ant International’s commitment to community empowerment, sustai
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom